Abcam Competitors

AbCellera Biologics (NASDAQ:ABCL) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for AbCellera Biologics and Abcam, as provided by MarketBeat.com.

AbCellera Biologics currently has a consensus target price of $52.80, suggesting a potential upside of 90.41%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 9.29%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, equities research analysts clearly believe AbCellera Biologics is more favorable than Abcam.

Profitability

This table compares AbCellera Biologics and Abcam's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares AbCellera Biologics and Abcam's gross revenue, earnings per share (EPS) and valuation.

Summary

AbCellera Biologics beats Abcam on 3 of the 3 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Valuation and Earnings

This table compares Sana Biotechnology and Abcam's gross revenue, earnings per share and valuation.

Profitability

This table compares Sana Biotechnology and Abcam's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for Sana Biotechnology and Abcam, as reported by MarketBeat.

Sana Biotechnology presently has a consensus price target of $40.00, suggesting a potential upside of 72.19%. Abcam has a consensus price target of $22.00, suggesting a potential upside of 9.29%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Abcam.

Summary

Sana Biotechnology beats Abcam on 2 of the 3 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Seer (NASDAQ:SEER) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Valuation & Earnings

This table compares Abcam and Seer's revenue, earnings per share and valuation.

Profitability

This table compares Abcam and Seer's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abcam and Seer, as reported by MarketBeat.com.

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 9.29%. Seer has a consensus price target of $68.00, suggesting a potential upside of 40.76%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Abcam.

Summary

Seer beats Abcam on 2 of the 3 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Profitability

This table compares Abcam and Nuvation Bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Abcam and Nuvation Bio, as reported by MarketBeat.com.

Abcam presently has a consensus price target of $22.00, suggesting a potential upside of 9.29%. Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 73.91%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Abcam.

Valuation & Earnings

This table compares Abcam and Nuvation Bio's revenue, earnings per share and valuation.

Summary

Nuvation Bio beats Abcam on 3 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares ImmunityBio and Abcam's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for ImmunityBio and Abcam, as reported by MarketBeat.

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 50.15%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 9.29%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Abcam.

Valuation and Earnings

This table compares ImmunityBio and Abcam's revenue, earnings per share (EPS) and valuation.

Summary

ImmunityBio beats Abcam on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares BioAtla and Abcam's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for BioAtla and Abcam, as reported by MarketBeat.

BioAtla currently has a consensus target price of $58.00, suggesting a potential upside of 23.19%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 9.29%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Abcam.

Valuation and Earnings

This table compares BioAtla and Abcam's revenue, earnings per share (EPS) and valuation.

Summary

BioAtla beats Abcam on 3 of the 3 factors compared between the two stocks.